Cardinal Health Upgraded to Buy by Citi, Price Target Raised to $244
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Yahoo Finance
- Rating Upgrade: Citi upgraded Cardinal Health (CAH) from Neutral to Buy, raising the price target from $190 to $244, reflecting confidence in the company's growth in specialist assets alongside solid performance in its core pharmaceutical distribution business.
- Specialist Business Expansion: The addition of newly acquired assets like Solaris Health is expected to enhance operational efficiency and drive revenue growth, further solidifying Cardinal Health's market position in the healthcare services sector.
- Cautious Outlook: While the company remains cautious about its Global Medical Products and Distribution business, it believes there is potential upside compared to consensus forecasts, indicating an optimistic outlook for future growth.
- Market Positioning: As a large U.S. healthcare services and products company, Cardinal Health distributes pharmaceuticals and medical supplies globally, operating in Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution, showcasing its extensive influence in the healthcare industry.
Analyst Views on CAH
Wall Street analysts forecast CAH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAH is 213.91 USD with a low forecast of 187.00 USD and a high forecast of 232.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 213.460
Low
187.00
Averages
213.91
High
232.00
Current: 213.460
Low
187.00
Averages
213.91
High
232.00
About CAH
Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. Its segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States, as well as it owns urology MSO. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
